Meeting Summary from 2016 Innovation and Biomarkers in Cancer Drug Development Meeting + 2018 IBCD Meeting Preview

The Innovation and Biomarkers in Cancer Drug Development (IBCD) meeting was held September 8-9, 2016 in Brussels, Belgium and highlighted cooperative approaches to cancer drug development with new cancer biomarkers. This meeting was a collaboration between the European Organisation for Research and Treatment of Cancer (EORTC), NCI, the European Medicines Agency (EMA), and the American Association for Cancer Research (AACR). A summary of the meeting discussions was published in the European Journal of Cancer in August 2017.

Several DCTD staff were involved in the planning and implementation of this conference, including the following:

Robert J. Kinders, PhD, Frederick National Laboratory for Cancer Research/Office of the Director
Speaker

Tracy Lively, PhD, Cancer Diagnosis Program
Organizing Committee/Session Chair

Shakun Malik, MD, Cancer Therapy Evaluation Program
Scientific Committee/Session Chair/Speaker

Tawnya McKee, PhD, Cancer Diagnosis Program
Scientific Committee/Session Chair

Helen Moore, PhD, Cancer Diagnosis Program
Scientific Committee/Session Chair

Jeff Moscow, MD, Cancer Therapy Evaluation Program
Scientific Committee/Session Chair

The next IBCD meeting will convene in November 2018 in Brussels, Belgium.